Genomic analysis for metastatic breast cancer(MBC) patients * Participant (Inclusion criteria) 1. Patients who diagnosed metastatic/stage IV breast cancer 2. Patients who were not received treatment for metastatic breast cancer on palliative setting * Process (1) Tissue/ Blood sample * At diagnosis, MBC tissue / blood sample (20cc) will be obtained. * At disease progression after 1st line treatment for MBC, blood sample (20cc) will be obtained (tissue; optional) (2) WES, RNASeq, ctDNA, Exosome * We will analyze genomic characteritics using WES, RNASeq, ctDNA, Exosome.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
300
WES, RNASeq, ctDNA, Exosome
Samsung Medical Center, Sungkyunkwan University School of Medicine
Seoul, South Korea
RECRUITINGGenomic profiling of MBC patients
Gemetic alteration frequency, the association between genetic alteration and survival
Time frame: 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.